To our knowledge, this is the first report that HNSCC can produce active IL-1β via P2X7/NLRP3 inflammasome pathways, and also the first trial to reduce HNSCC survival and invasiveness by blocking P2X7R/NLRP3 inflammasome. The gene discussed is IL1B; the disease is head and neck squamous cell carcinoma.